logo-loader
RNS
viewOmega Diagnostics Group Plc

Grant of Share Options

/**/ h1{margin-right:0cm;margin-left:0cm;font-size:24.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h2{margin-right:0cm;margin-left:0cm;font-size:18.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h3{margin-right:0cm;margin-left:0cm;font-size:13.5pt;font-family:"Times New Roman","serif";font-weight:bold;}h4{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h5{margin-right:0cm;margin-left:0cm;font-size:10.0pt;font-family:"Times New Roman","serif";font-weight:bold;}h6{margin-top:0cm;margin-right:41.3pt;margin-bottom:0cm;margin-left:0cm;margin-bottom:.0001pt;text-align:justify;font-size:10.0pt;font-family:"Arial","sans-serif";color:black;font-weight:bold;}p{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}ol{margin-bottom:0cm;}ul{margin-bottom:0cm;}link{ color: blue } visited{ color: purple } .ci{size:612.0pt 792.0pt;margin:14.2pt 1.0cm 0cm 1.0cm;}div.ci{}p.eu{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: center}span.es{font-size:10.0pt;font-family:"Arial","sans-serif"}p.ev{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold}p.ew{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align: center}p.ex{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align:justify}span.eo{font-size:10.0pt; font-family:"Arial","sans-serif"}p.ey{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:0cm;text-align:justify}span.em{font-size: 10.0pt;font-family:"Arial","sans-serif";color:#212721} p.ez{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:3.0pt;text-align:justify}span.fa{font-size:10.0pt;font-family:"Arial","sans-serif";color:#212721}span.ek{font-size:10.0pt;font-family:"Arial","sans-serif";color:#212721}span.ce{}span.cf{}p.fb{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:3.0pt;text-align:justify}span.fc{font-size:10.0pt;font-family:"Arial","sans-serif"; color:#212721}p.fd{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-div: italic; text-align: justify}span.eh{font-size:10.0pt;font-family:"Arial","sans-serif";color:black}p.fe{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-right: 41.3pt; text-align: justify} table.ff{margin-left:-5.4pt;border-collapse:collapse}tr.ea{height:11.45pt}td.ed{width:234.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.45pt}p.fg{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify}td.eb{width:231.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:11.45pt}p.fh{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";text-align: right}tr.dx{height:12.0pt}td.dz{width:234.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.0pt}td.dy{width:231.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:12.0pt}tr.du{height:9.6pt} td.dw{width:234.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:9.6pt}td.dv{width:231.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:9.6pt}tr.dr{height:4.0pt}td.dt{width:234.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.0pt}td.ds{width:231.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.0pt}tr.do{height:4.5pt}td.dq{width:234.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.5pt}td.dp{width:231.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:4.5pt}tr.dl{height:5.4pt}td.dn{width:234.4pt;padding:0cm 5.4pt 0cm 5.4pt; height:5.4pt} td.dm{width:231.35pt;padding:0cm 5.4pt 0cm 5.4pt; height:5.4pt}p.fi{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; margin-right: 2.2pt; text-align: justify}p.fj{margin:0cm;margin-bottom:.0001pt;font-size:12.0pt;font-family:"Times New Roman","serif";font-weight: bold; text-align: justify; text-autospace: none}table.fk{margin-left:-5.4pt;border-collapse:collapse;border:none}td.df{width:25.6pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}h2.dg{margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left: 36.0pt;text-align:justify;text-indent:-36.0pt; text-autospace:none;vertical-align:baseline}span.dh{font-size:11.0pt;font-family:"Calibri","sans-serif"}td.dd{width:498.3pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}p.i,li.i,div.i{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";}span.de{font-size:11.0pt;font-family: "Calibri","sans-serif"} td.dc{width:25.6pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.db{width:243.0pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.da{width:244.5pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.cz{width:498.3pt;border-top:none; border-left:none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}span.cy{font-size:11.0pt;font-family: "Calibri","sans-serif";color:black}table.fl{border-collapse:collapse;border:none}td.cx{width:73.3pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.cw{width:77.95pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.cv{width:73.3pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.cu{width:77.95pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt} p.fm{margin-right:0cm;margin-left:0cm;font-size:12.0pt;font-family:"Times New Roman","serif";margin-top:6.0pt;margin-right:0cm;margin-bottom: 6.0pt;margin-left:18.0pt;text-indent:-18.0pt; text-autospace:none;vertical-align:baseline}span.cs{font-size:11.0pt;font-family:Symbol}td.cq{width:48.55pt;border:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.cp{width:52.35pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.co{width:39.55pt;border:solid windowtext 1.0pt; border-left:none;padding:0cm 5.4pt 0cm 5.4pt}td.cn{width:48.55pt;border:solid windowtext 1.0pt; border-top:none;padding:0cm 5.4pt 0cm 5.4pt}td.cm{width:52.35pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}td.cl{width:39.55pt;border-top:none;border-left: none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt; padding:0cm 5.4pt 0cm 5.4pt}tr.ck{page-break-inside:avoid}p.ch,li.ch,div.ch{margin-top:6.0pt;margin-right:0cm;margin-bottom:6.0pt;margin-left:0cm;text-align:justify;font-size:10.0pt;font-family:"Arial","sans-serif";} /**/
RNS Number : 2383V
Omega Diagnostics Group PLC
02 December 2019
 

 

 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Grant of Share Options and Notification of Director / PDMR Dealings

 

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, food intolerance and allergy testing, announces that the Group's Remuneration Committee and the Board have approved the grant of 500,000 options ("New Options") over ordinary shares of 4 pence each ("Ordinary Shares") to Jeremy Millard, Non-Executive Director, pursuant to the Group's existing share option schemes.

All New Options were granted with an exercise price of 10 pence each, being the closing middle market price on 29 November 2019. The New Options will vest over three years, one third vesting on each anniversary of the grant date.

The grant of 500,000 New Options equates to 0.33 per cent. of the Group's current issued share capital. In total, 9,420,406 options are now under grant but not exercised, which equates to 6.3 per cent. of the Group's current issued share capital.

 

The FCA notification, made in accordance with the requirements of the EU Market Abuse Regulation is appended below.

 

The information communicated in this announcement is inside information for the purposes of Article 7 of EU Regulation 596/2014.

 

 

Contacts: 

 

Omega Diagnostics Group PLC                         

Tel: 01259 763 030

Bill Rhodes, Interim Non-Executive Chairman

Colin King, Chief Executive                             

www.omegadiagnostics.com

Kieron Harbinson, Group Finance Director

 

 

Mob: 07740 084452

 

 

finnCap Ltd                                              

Tel: 020 7220 0500

Geoff Nash/Hannah Boros (Corporate Finance)

 

Camille Gochez (Corporate Broking)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or [email protected]

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

 

 

Details of the person discharging managerial responsibilities/person closely associated

a)

Name:

Jeremy Millard

 

Reason for the notification

a)

Position/status:

Non-Executive Director

b)

Initial notification/Amendment:

Initial Notification

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name:

Omega Diagnostics Group Plc

b)

LEI:

2138007U9P4BTZTYIR92

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument:

Identification code:

Ordinary Shares of 0.5 pence each

GB00B1VCP282

 

b)

Nature of the transaction:

Grant of options over Ordinary Shares

c)

Price(s) and volume(s):

Price(s)

Volume(s)

n/a

500,000

 

d)

Aggregated information:

·     Aggregated volume:

·     Price:

Single transaction as in 4 c) above

Price(s)

Volume(s)

Total

n/a

500,000

n/a

 

e)

Date of the transaction:

2 December 2019

f)

Place of the transaction:

n/a

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
MSCFSSFAFFUSELE

Quick facts: Omega Diagnostics Group Plc

Price: 15.25

Market: AIM
Market Cap: £22.92 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE